Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2014, Article ID 612674, 6 pages
http://dx.doi.org/10.1155/2014/612674
Research Article

Primary Circulating Prostate Cells Are Not Detected in Men with Low Grade Small Volume Prostate Cancer

1Hospital Carabineros of Chile, Nunoa, 7770199 Santiago, Chile
2Circulating Tumor Cell Unit, Faculty of Medicine, University Mayor, Las Condes, 7550224 Santiago, Chile
3Institute of Bio-Oncology, Providencia, 7500710 Santiago, Chile
4Faculty of Medicine, Diego Portales University, Manuel Rodríguez Sur 415, 8370179 Santiago, Chile

Received 9 May 2014; Revised 12 July 2014; Accepted 28 July 2014; Published 19 August 2014

Academic Editor: M. Roach

Copyright © 2014 Nigel P. Murray et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. MINSAL: Ministry of Health Chile, “Cancer Statistics,” http://web.minsal.cl/.
  2. R. S. Pungalia, A. V. D'Amico, W. J. Catalona et al., “Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level,” Cancer, vol. 106, pp. 1507–1513, 2006. View at Google Scholar
  3. C. B. Bozeman, B. S. Carver, J. A. Eastham, and D. D. Venable, “Treatment of chronic prostatitis lowers serum prostate specific antigen,” Journal of Urology, vol. 167, no. 4 I, pp. 1723–1726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Jemel, R. Siegel, E. Ward et al., “Cancer statistics,” Cancer Journal for Clinicians, vol. 56, pp. 106–130, 2006. View at Google Scholar
  5. J. S. Krumholtz, G. F. Carvalhal, C. G. Ramos et al., “Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features,” Urology, vol. 60, no. 3, pp. 469–473, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. I. M. Thompson, P. J. Goodman, and C. M. Tangen, “The influence of finisteride on the development of prostate cancer,” The New England Journal of Medicine, vol. 349, pp. 215–224, 2003. View at Google Scholar
  7. W. A. Sakr, D. J. Grignon, J. D. Crissman et al., “HGPIN and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases,” In Vivo, vol. 8, pp. 439–443, 1994. View at Google Scholar
  8. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., “Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter,” The New England Journal of Medicine, vol. 350, pp. 2239–2246, 2004. View at Google Scholar
  9. F. H. Schroeder, J. Hugosson, and M. J. Roobol, “Prostate cancer mortality at 11 years of follow up,” The New England Journal of Medicine, vol. 366, pp. 981–990, 2012. View at Publisher · View at Google Scholar
  10. F. H. Schroeder, J. Hugosson, M. J. Roobol et al., “Screening and prostate cancer mortality in a randomized Eurpoean study,” The New England Journal of Medicine, vol. 360, pp. 1320–1328, 2009. View at Google Scholar
  11. J. Hugosson, S. Carlsson, G. Aus et al., “Mortality results from the Göteborg randomised population-based prostate-cancer screening trial,” The Lancet Oncology, vol. 11, no. 8, pp. 725–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei, “Incidence of initial local therapy among men with lower-risk prostate cancer in the United States,” Journal of the National Cancer Institute, vol. 98, no. 16, pp. 1134–1141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. B. W. Rietbergen, A. E. B. Kruger, R. Kranse, and F. H. Schröder, “Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program,” Urology, vol. 49, no. 6, pp. 875–880, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. N. P. Murray, E. Reyes, P. Tapia et al., “Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy,” Archivos Espanoles de Urologia, vol. 64, no. 10, pp. 961–971, 2011. View at Google Scholar · View at Scopus
  15. E. Borgen, B. Naume, J. M. Nesland et al., “Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells,” Cytotherapy, vol. 1, no. 5, pp. 377–388, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Rubin, M. Zhou, S. M. Dhanasekaran et al., “α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer,” Journal of the American Medical Association, vol. 287, no. 13, pp. 1662–1670, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. J. Tosoian, B. J. Trock, P. Landis et al., “Active surveillance program for prostate cancer: an update of the Johns Hopkins experience,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2185–2190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. I. Epstein, P. C. Walsh, M. Carmichael, and C. B. Brendler, “Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer,” Journal of the American Medical Association, vol. 271, no. 5, pp. 368–374, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Draisma, R. Etzioni, A. Tsodikov et al., “Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context,” Journal of the National Cancer Institute, vol. 101, no. 6, pp. 374–383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. J. Bastian, L. A. Mangold, J. I. Epstein, and A. W. Partin, “Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis,” Cancer, vol. 101, no. 9, pp. 2001–2005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Bastian, B. H. Carter, A. Bjartell et al., “Insignificant prostate cancer and active surveillance: from definition to clinical implications,” European Urology, vol. 55, no. 6, pp. 1321–1330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. C. N. van den Bergh, M. Essink-Bot, M. J. Roobol et al., “Anxiety and distress during active surveillance for early prostate cancer,” Cancer, vol. 115, no. 17, pp. 3868–3878, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. S. Borden, J. L. Wright, J. Kim et al., “An abnormal digital rectal examination is an independent predictor of Gleason >/=7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men,” BJU International, vol. 99, pp. 559–563, 2006. View at Google Scholar
  24. M. Garzotto, L. Collins, R. Priest et al., “Nomogram for the prediction of high-grade prostate cancer on ultrasoundguided needle biopsy,” Journal of Clinical Oncology, vol. 23, no. 16, 408S pages, 2005. View at Google Scholar
  25. S. C. Krejcarek, M. Chen, A. A. Renshaw, M. Loffredo, B. Sussman, and A. V. D'Amico, “Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer,” Urology, vol. 69, no. 3, pp. 515–519, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. M. Mian, Y. Naya, K. Okihara, F. Vakar-Lopez, P. Troncoso, and R. J. Babaian, “Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy,” Urology, vol. 60, no. 5, pp. 836–840, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. N. P. Murray, E. Reyes, N. Orellana et al., “Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease,” The Scientific World Journal, vol. 2013, Article ID 762064, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Eschwège, S. Moutereau, S. Droupy et al., “Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study,” British Journal of Cancer, vol. 100, no. 4, pp. 608–610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. W. Davis, H. Nakanishi, V. S. Kumar et al., “Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer,” Journal of Urology, vol. 179, no. 6, pp. 2187–2191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. L. Stott, R. J. Lee, S. Nagrath et al., “Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer,” Science Translational Medicine, vol. 2, no. 25, pp. 25ra–23ra, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Fizazi, L. Chauveinc, D. Prapotnich et al., “High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity,” Annals of Oncology, vol. 18, no. 3, pp. 518–521, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. N. P. Murray, E. Reyes, L. Badínez et al., “Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications,” Journal of Oncology, vol. 2013, Article ID 165014, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. F. B. Thomsen, N. Marcussen, K. D. Berg et al., “Repeated biopsies in prostate cancer patients on active surveillance: clinical implications of interobserver variation in histopathologic al assessment,” British Journal of Urology, 2014. View at Publisher · View at Google Scholar